Skip to content

Study · Animal study (in vivo) · mouse · 2023

9 results

Protective effect of exogenous peroxiredoxin 6 and thymic peptide thymulin on BBB conditions in an experimental model of multiple sclerosis.

Lunin SM, Novoselova EG, Glushkova OV, Parfenyuk SB, Kuzekova AA, Novoselova TV, Sharapov MG, Mubarakshina EK, Goncharov RG, Khrenov MO

Archives of biochemistry and biophysics24 Aug 2023Cited by 5 (Europe PMC)

PMID37633587 (opens in a new tab)DOI10.1016/j.abb.2023.109729 (opens in a new tab)PepBankPUB-37633587
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with EAE, thymulin improved BBB integrity as measured by Evans blue dye accumulation.

    In plain wordsIn mice with EAE, thymulin improved the brain barrier measured with Evans blue dye.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseEvans blue dye accumulation
    Study

    mousen: not reported in source

    Relapsing-remitting experimental autoimmune encephalomyelitis
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both thymulin and Prdx6 significantly improved the condition of the BBB, which was impaired by EAE induction, as measured by Evans blue dye accumulation, tight-junction protein loss in brain tissue, and lymphocyte infiltration through the BBB.
    1 context sentence
    Summary · context
    on the blood‒brain barrier (BBB) condition and general health status of animals with relapsing-remitting experimental autoimmune encephalomyelitis (EAE), which is a model of multiple sclerosis in humans.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with EAE, thymulin reduced BBB impairment measured by tight-junction protein loss.

    In plain wordsIn mice with EAE, thymulin reduced brain barrier damage measured by loss of junction proteins.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseTight-junction protein loss
    Study

    mousen: not reported in source

    Relapsing-remitting experimental autoimmune encephalomyelitis
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both thymulin and Prdx6 significantly improved the condition of the BBB, which was impaired by EAE induction, as measured by Evans blue dye accumulation, tight-junction protein loss in brain tissue, and lymphocyte infiltration through the BBB.
    1 context sentence
    Summary · context
    on the blood‒brain barrier (BBB) condition and general health status of animals with relapsing-remitting experimental autoimmune encephalomyelitis (EAE), which is a model of multiple sclerosis in humans.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with EAE, thymulin improved BBB integrity measured by lymphocyte infiltration.

    In plain wordsIn mice with EAE, thymulin reduced brain barrier damage measured by immune cell entry.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseLymphocyte infiltration through BBB
    Study

    mousen: not reported in source

    Relapsing-remitting experimental autoimmune encephalomyelitis
    Outcome group
    Immune response · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both thymulin and Prdx6 significantly improved the condition of the BBB, which was impaired by EAE induction, as measured by Evans blue dye accumulation, tight-junction protein loss in brain tissue, and lymphocyte infiltration through the BBB.
    1 context sentence
    Summary · context
    on the blood‒brain barrier (BBB) condition and general health status of animals with relapsing-remitting experimental autoimmune encephalomyelitis (EAE), which is a model of multiple sclerosis in humans.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with EAE, thymulin-associated BBB improvement accompanied significant symptom amelioration.

    In plain wordsIn mice with EAE, thymulin-associated brain barrier improvement accompanied reduced symptoms.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseEAE symptoms
    Study

    mousen: not reported in source

    Relapsing-remitting experimental autoimmune encephalomyelitis
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The effect was associated with significant amelioration of EAE symptoms.
    2 context sentences
    Summary · context
    Both thymulin and Prdx6 significantly improved the condition of the BBB, which was impaired by EAE induction, as measured by Evans blue dye accumulation, tight-junction protein loss in brain tissue, and lymphocyte infiltration through the BBB.
    Summary · context
    on the blood‒brain barrier (BBB) condition and general health status of animals with relapsing-remitting experimental autoimmune encephalomyelitis (EAE), which is a model of multiple sclerosis in humans.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice with EAE, thymulin decreased immune activation as judged by serum IL-6.

    In plain wordsIn mice with EAE, thymulin reduced immune activation measured by serum IL-6.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseSerum IL-6
    Study

    mousen: not reported in source

    Relapsing-remitting experimental autoimmune encephalomyelitis
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Thymulin treatment was accompanied by a decrease in immune cell activation as judged by interleukin-6, -17, and interferon-gamma cytokine levels in serum and NF-kappaB cascade activation in splenocytes of mice with EAE.
    1 context sentence
    Summary · context
    on the blood‒brain barrier (BBB) condition and general health status of animals with relapsing-remitting experimental autoimmune encephalomyelitis (EAE), which is a model of multiple sclerosis in humans.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice with EAE, thymulin decreased immune activation as judged by serum IL-17.

    In plain wordsIn mice with EAE, thymulin reduced immune activation measured by serum IL-17.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseSerum IL-17
    Study

    mousen: not reported in source

    Relapsing-remitting experimental autoimmune encephalomyelitis
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Thymulin treatment was accompanied by a decrease in immune cell activation as judged by interleukin-6, -17, and interferon-gamma cytokine levels in serum and NF-kappaB cascade activation in splenocytes of mice with EAE.
    1 context sentence
    Summary · context
    on the blood‒brain barrier (BBB) condition and general health status of animals with relapsing-remitting experimental autoimmune encephalomyelitis (EAE), which is a model of multiple sclerosis in humans.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In mice with EAE, thymulin decreased immune activation as judged by serum interferon-gamma.

    In plain wordsIn mice with EAE, thymulin reduced immune activation measured by serum interferon-gamma.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseSerum interferon-gamma
    Study

    mousen: not reported in source

    Relapsing-remitting experimental autoimmune encephalomyelitis
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Thymulin treatment was accompanied by a decrease in immune cell activation as judged by interleukin-6, -17, and interferon-gamma cytokine levels in serum and NF-kappaB cascade activation in splenocytes of mice with EAE.
    1 context sentence
    Summary · context
    on the blood‒brain barrier (BBB) condition and general health status of animals with relapsing-remitting experimental autoimmune encephalomyelitis (EAE), which is a model of multiple sclerosis in humans.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In mice with EAE, thymulin decreased immune activation as judged by splenocyte NF-kappaB activation.

    In plain wordsIn mice with EAE, thymulin reduced splenocyte NF-kappaB activation.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseSplenocyte NF-kappaB activation
    Study

    mousen: not reported in source

    Relapsing-remitting experimental autoimmune encephalomyelitis
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Thymulin treatment was accompanied by a decrease in immune cell activation as judged by interleukin-6, -17, and interferon-gamma cytokine levels in serum and NF-kappaB cascade activation in splenocytes of mice with EAE.
    1 context sentence
    Summary · context
    on the blood‒brain barrier (BBB) condition and general health status of animals with relapsing-remitting experimental autoimmune encephalomyelitis (EAE), which is a model of multiple sclerosis in humans.

Studies that did not test the peptide alone1

In this study, Thymulin (serum thymic factor) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymulin (serum thymic factor).

  1. 09AnimalNot a test of Thymulin (serum thymic factor) aloneAnimal study (in vivo)Efficacy outcome

    In mice with EAE, simultaneous thymulin and Prdx6 administration produced complete symptomatic restoration.

    In plain wordsIn mice with EAE, combined thymulin and Prdx6 treatment produced complete recovery from symptoms.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseSymptoms with combined thymulin and Prdx6
    Study

    mousen: not reported in source

    Relapsing-remitting experimental autoimmune encephalomyelitis
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    The simultaneous administration of thymulin and Prdx6 resulted in complete symptomatic restoration of mice with EAE.
    1 context sentence
    Summary · context
    on the blood‒brain barrier (BBB) condition and general health status of animals with relapsing-remitting experimental autoimmune encephalomyelitis (EAE), which is a model of multiple sclerosis in humans.

    In this study, Thymulin (serum thymic factor) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymulin (serum thymic factor).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:55 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.